Specialty firm Covis to acquire US drug rights from GSK
This article was originally published in Scrip
Executive Summary
Covis Pharma, a Swiss based global specialty company, has entered into an agreement with GlaxoSmithKline to acquire full commercial rights for Fortaz (ceftazidime), Zinacef (cefuroxime), Lanoxin (digoxin), Parnate (tranylcypromine sulfate) and Zantac injection (ranitidine HCl) in the US and Puerto Rico.